A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy

Running, not enrolling · Phase 2 · Has a placebo group

Conditions studied: Focal Epilepsy

In brief

The XEN1101 Phase 2 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of increasing doses of XEN1101 administered as adjunctive treatment in adult patients diagnosed with focal epilepsy, followed by an optional open-label extension (OLE).

Key facts

Study ID
NCT03796962
Run by
Xenon Pharmaceuticals Inc.
People needed
325
Starts
2019-01-30
Expected to finish
2028-10-01
Last updated by the study team
2024-09-24

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.